The Silverstein Foundation, REGENXBIO, and OrbiMed Launch Prevail Therapeutics
The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO Inc. (“REGENXBIO”), and OrbiMed today announced the formation and launch of Prevail Therapeutics, Inc., (“Prevail”), a new company focused on discovering and developing novel biologic therapies for Parkinson’s Disease and other neurodegenerative diseases.